This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.20% per year. These returns cover a period from January 1, 1988 through April 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
BioCryst Pharmaceuticals (BCRX) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
BioCryst (BCRX) delivered earnings and revenue surprises of -9.68% and -42.43%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: BioCryst Pharmaceuticals (BCRX) Q2 Earnings Expected to Decline
by Zacks Equity Research
BioCryst (BCRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BioCryst Down Despite Hereditary Angioedema Study Meets Goal
by Zacks Equity Research
BioCryst's (BCRX) phase III study on BCX7353 for the prevention of hereditary angioedema attacks meets the primary endpoint for both doses (110mg/150 mg). Shares depreciate despite this upside.
Do Options Traders Know Something About BioCryst Pharmaceuticals (BCRX) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to BioCryst Pharmaceuticals (BCRX) stock based on the movements in the options market lately.
BioCryst Pharmaceuticals (BCRX) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
BioCryst (BCRX) delivered earnings and revenue surprises of 0.00% and 101.96%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate BioCryst Pharmaceuticals (BCRX) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
BioCryst (BCRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Implied Volatility Surging for BioCryst Pharmaceuticals (BCRX) Stock Options
by Zacks Equity Research
BioCryst Pharmaceuticals (BCRX) needs investors to pay close attention to the stock based on moves in the options market lately.
Analysts Estimate BioCryst Pharmaceuticals (BCRX) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
BioCryst (BCRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BioCryst Pharmaceuticals (BCRX) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
BioCryst (BCRX) delivered earnings and revenue surprises of -12.00% and -42.60%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: BioCryst Pharmaceuticals (BCRX) Q3 Earnings Expected to Decline
by Zacks Equity Research
BioCryst (BCRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Grifols (GRFS) Surges: Stock Moves 5.4% Higher
by Zacks Equity Research
Grifols (GRFS) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
BioCryst Pharmaceuticals (BCRX) Looks Good: Stock Adds 6% in Session
by Zacks Equity Research
BioCryst Pharmaceuticals (BCRX) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
BioCryst Pharmaceuticals (BCRX) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
BioCryst (BCRX) delivered earnings and revenue surprises of 17.39% and 228.79%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Idera Stock Down, Study on Dermatomyositis Candidate Fails
by Zacks Equity Research
Shares of Idera (IDRA) decline following the failure of a phase II study of its pipeline candidate, IMO-8400, on adult patients with dermatomyositis.
Options Traders Expect Huge Moves in BioCryst (BCRX) Stock
by Zacks Equity Research
Investors in BioCryst (BCRX) need to pay close attention to the stock based on moves in the options market lately.
Is the Options Market Predicting a Spike in BioCryst (BCRX) Stock?
by Zacks Equity Research
Investors need to pay close attention to BioCryst (BCRX) stock based on the movements in the options market lately.
BioCryst (BCRX) & Idera (IDRA) Announce Merger, Shares Fall
by Zacks Equity Research
Shares of BioCryst Pharmaceuticals (BCRX) and Idera Pharmaceuticals (IDRA) plunge following the announcement of their merger.
Is the Options Market Predicting a Spike in BioCryst (BCRX) Stock?
by Zacks Equity Research
Investors need to pay close attention to BioCryst (BCRX) stock based on the movements in the options market lately.
Implied Volatility Surging for BioCryst (BCRX) Stock Options
by Zacks Equity Research
Investors in BioCryst Pharmaceuticals, Inc. (BCRX) need to pay close attention to the stock based on moves in the options market lately.
What's in the Cards for Ecolab (ECL) this Earnings Season?
by Zacks Equity Research
Ecolab Inc. (ECL), a leading provider of water, hygiene and energy technologies and services, is expected to report first-quarter 2017 results on May 2.
Can Cardinal Health (CAH) Bring On a Beat in Q3 Earnings?
by Zacks Equity Research
Cardinal Health (CAH), a global player in the healthcare services and products space, is set to report third-quarter fiscal 2017 results on May 1, before the bell.
Will Baxter International (BAX) Disappoint in Q1 Earnings?
by Zacks Equity Research
Baxter International Inc. (BAX) is scheduled to report first-quarter 2017 earnings on Apr 26, before the opening bell.
Is a Surprise in Store for C.R. Bard (BCR) in Q1 Earnings?
by Zacks Equity Research
CR Bard Inc. (BCR) is scheduled to report first-quarter 2017 earnings, after market close on Apr 26.
Will Stryker (SYK) Deliver a Beat this Earnings Season?
by Zacks Equity Research
Stryker Corporation (SYK), a leading player in the medical technology space, is set to report first-quarter 2017 results on Apr 25 after the bell.
Teva Launches Authorized Generic of Allergan's Minastrin
by Zacks Equity Research
Teva Pharmaceutical Industries Ltd. (TEVA) recently launched an authorized generic version of Allergan plc???s (AGN) oral contraceptive, Minastrin 24 Fe1, in the U.S.